Cargando…

COVID-19 and Disease-Modifying Anti-rheumatic Drugs

PURPOSE OF REVIEW: Patients on disease-modifying anti-rheumatic drugs (DMARDs) remain concerned about potential risks of severe COVID-19 outcomes. Meanwhile, several DMARDs have been proposed as COVID-19 therapies. RECENT FINDINGS: In patients with autoimmune diseases, baseline glucocorticoid use is...

Descripción completa

Detalles Bibliográficos
Autores principales:	D’Silva, Kristin M., Wallace, Zachary S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Infections and Arthritis (K Winthrop, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065312/ https://www.ncbi.nlm.nih.gov/pubmed/33893890 http://dx.doi.org/10.1007/s11926-021-00998-9

Ejemplares similares

Differentiating Disease Flare From Infection: A Common Problem in Rheumatology. Do 18F-FDG PET/CT Scans and Novel Biomarkers Hold The Answer?
por: Mabey, Elizabeth, et al.
Publicado: (2018)

Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis
por: Su, Yu-Jih, et al.
Publicado: (2023)

Costs of drugs for treatment of rheumatic diseases
por: Westhovens, Rene, et al.
Publicado: (2016)

Incident systemic rheumatic disease following COVID-19
por: Hsu, Tiffany Y-T, et al.
Publicado: (2021)

Central Nervous System Infections in Immunocompromised Patients
por: Pruitt, Amy A.
Publicado: (2021)

Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
por: Andreica, Ioana, et al.
Publicado: (2022)

Exercise modifies the disease-relevant gut microbial shifts in post-traumatic osteoarthritis rats
por: Hao, Xiaoxia, et al.
Publicado: (2022)

Pros and Cons of Skeletal Medications in the COVID-19 Era
por: Tsourdi, Elena, et al.
Publicado: (2022)

COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune rheumatic Diseases (COVIAAD): safety, immunogenicity and antibody persistence at 12 months following Moderna Spikevax primary series
por: Colmegna, Ines, et al.
Publicado: (2023)

Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy
por: Vanni, Kathleen MM, et al.
Publicado: (2022)

Temporal trends in severe COVID-19 outcomes in patients with rheumatic disease: a cohort study
por: Jorge, April, et al.
Publicado: (2021)

Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
por: Santos, Cristiana Sieiro, et al.
Publicado: (2021)

Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
por: Sattui, Sebastian Eduardo, et al.
Publicado: (2021)

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
por: DiIorio, Michael, et al.
Publicado: (2022)

Methods to improve medication adherence in patients with chronic inflammatory rheumatic diseases: a systematic literature review
por: Lavielle, Matthieu, et al.
Publicado: (2018)

Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis
por: Aletaha, Daniel, et al.
Publicado: (2019)

Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
por: Kivitz, Alan, et al.
Publicado: (2014)

Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?
por: Laster, Andrew J, et al.
Publicado: (2022)

Patients’ Attitudes and Experiences of Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis and Spondyloarthritis: A Qualitative Synthesis
por: Kelly, Ayano, et al.
Publicado: (2018)

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
por: Fleischmann, Roy, et al.
Publicado: (2017)

In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora
por: Kussmann, Manuel, et al.
Publicado: (2021)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study
por: Mehta, Bella, et al.
Publicado: (2019)

‘Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?’
por: Goodman, Susan M, et al.
Publicado: (2020)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

The Dynamic Interplay of Healthy Lifestyle Behaviors for Cardiovascular Health
por: Kris-Etherton, Penny M., et al.
Publicado: (2022)

Psychosis in Alzheimer’s Disease
por: Ballard, Clive, et al.
Publicado: (2020)

Risk of COVID-19 infection in patients with rheumatic disease taking disease-modifying anti-rheumatic drugs
por: Yousefghahari, Behnaz, et al.
Publicado: (2021)

DAPSA and ultrasound show different perspectives of psoriatic arthritis disease activity: results from a 12-month longitudinal observational study in patients starting treatment with biological disease-modifying antirheumatic drugs
por: Pukšić, Silva, et al.
Publicado: (2018)

Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases
por: Fragoulis, George E, et al.
Publicado: (2022)

A Review on the Effectivity of the Current COVID-19 Drugs and Vaccines: Are They Really Working Against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants?
por: Noor, Rashed
Publicado: (2021)

Food Insecurity and Cardiovascular Disease Risk
por: Liu, Yibin, et al.
Publicado: (2021)

Promising targets and drugs in rheumatoid arthritis: a module-based and cumulatively scoring approach
por: Li, Xingyan, et al.
Publicado: (2020)

Early-Onset Alzheimer’s Disease: What Is Missing in Research?
por: Ayodele, Temitope, et al.
Publicado: (2021)

Population-based user-perceived experience of Rheumatic?: a novel digital symptom-checker in rheumatology
por: Lundberg, Karin, et al.
Publicado: (2023)

Introduction and switching of biologic agents are associated with antidepressant and anxiolytic medication use: data on 42 815 real-world patients with inflammatory rheumatic disease
por: Bournia, Vasiliki-Kalliopi, et al.
Publicado: (2020)

Efficacy of non-pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases
por: Santos, Eduardo José Ferreira, et al.
Publicado: (2023)

Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease‐Modifying Antirheumatic Drug Treatment
por: Sparks, Jeffrey A., et al.
Publicado: (2019)

Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis
por: Plein, Sven, et al.
Publicado: (2020)

Alcohol Consumption and Cardiovascular Disease Risk: Placing New Data in Context
por: Hoek, Anna G., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_00tq7rpfrj5g2jth07646opovn